GBA1 and Parkinson disease: Finally, asymptomatic carriers of mutations in monogenic PD genes, e.g. LRRK2, or in risk genes like glucocerebrosidase (GBA), identified as first-degree relatives of PD patients, also represent potential prodromal target populations for disease-modification trials [19, 49, 50].